FDA's Proposed Regulations to Expand Access to Investigational Drugs for Treatment Use: The Status Quo in the Guise of Reform

被引：0
|
作者：
Rossen, Benjamin R. [1 ]
机构：
[1] Harvard Univ, Sch Law, Cambridge, MA 02138 USA
来源：
FOOD AND DRUG LAW JOURNAL | 2009年 / 64卷 / 01期
关键词：
UNITED-STATES; ACT; APPROVAL; FOOD; INNOVATION; CANCER;
D O I：
暂无
中图分类号：
TS2 [食品工业];
学科分类号：
0832 ;
摘要：
引用
收藏
页码：183 / 223
页数：41
相关论文
共 4 条
  • [1] Overview of FDA’s Expanded Access Program for Investigational Drugs
    Jonathan P. Jarow
    Peter Lurie
    Sarah Crowley Ikenberry
    Steven Lemery
    [J]. Therapeutic Innovation & Regulatory Science, 2017, 51 : 177 - 179
  • [2] Overview of FDA's Expanded Access Program for Investigational Drugs
    Jarow, Jonathan P.
    Lurie, Peter
    Ikenberry, Sarah Crowley
    Lemery, Steven
    [J]. THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (02) : 177 - 179
  • [3] OVERVIEW OF THE REPROPOSED AND FINAL IND REGULATIONS CONCERNED WITH THE TREATMENT USE AND SALE OF INVESTIGATIONAL NEW DRUGS - THE CONGRESSIONAL PERSPECTIVE
    EAGLSTEIN, WH
    [J]. FOOD AND DRUG LAW JOURNAL, 1988, 43 (02): : 435 - 442
  • [4] Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs
    Kraus, V. B.
    Simon, L. S.
    Katz, J. N.
    Neogi, T.
    Hunter, D.
    Guermazi, A.
    Karsdal, M. A.
    [J]. OSTEOARTHRITIS AND CARTILAGE, 2019, 27 (04) : 571 - 579
1